These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 27400657)

  • 21. Determinants of colorectal carcinoma screening amongst patients attending a public primary care health centre in Johor Bahru.
    Rizky NPH; Aznida FAA; Wan Fadhilah WI
    Med J Malaysia; 2021 May; 76(3):346-352. PubMed ID: 34031333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.
    Duffy MJ; van Rossum LG; van Turenhout ST; Malminiemi O; Sturgeon C; Lamerz R; Nicolini A; Haglund C; Holubec L; Fraser CG; Halloran SP
    Int J Cancer; 2011 Jan; 128(1):3-11. PubMed ID: 20824704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort.
    Chen LS; Yen AM; Chiu SY; Liao CS; Chen HH
    Lancet Oncol; 2011 Jun; 12(6):551-8. PubMed ID: 21592859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of personalised risk information compared to a positive/negative result on informed choice and intention to undergo colonoscopy following colorectal Cancer screening in Scotland (PERICCS) - a randomised controlled trial: study protocol.
    Steele RJC; Digby J; Chambers JA; O'Carroll RE
    BMC Public Health; 2019 Apr; 19(1):411. PubMed ID: 30991987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Colorectal cancer screening in the Netherlands: which faecal occult blood test?].
    Jansen JB; Blankenstein RM; Mulder CJ
    Ned Tijdschr Geneeskd; 2013; 157(16):A5744. PubMed ID: 23594870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attitudes towards faecal immunochemical testing in patients at increased risk of colorectal cancer: an online survey of GPs in England.
    von Wagner C; Stoffel S; Freeman M; Laszlo H; Nicholson BD; Sheringham J; Szinay D; Hirst Y
    Br J Gen Pract; 2018 Nov; 68(676):e757-e764. PubMed ID: 30297435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Why do some participants in colorectal cancer screening choose not to undergo colonoscopy following a positive test result? A qualitative study.
    Bie AKL; Brodersen J
    Scand J Prim Health Care; 2018 Sep; 36(3):262-271. PubMed ID: 30238859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial.
    Federici A; Giorgi Rossi P; Borgia P; Bartolozzi F; Farchi S; Gausticchi G
    J Med Screen; 2005; 12(2):83-8. PubMed ID: 15949119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rate and associated factors of refusal to perform immunochemical Faecal Occult Blood Test (iFOBT) among semi-urban communities.
    Syed Soffian SS; Safian N; Nawi AM; Ahmad SB; Chan HK; Abu Hassan MR
    PLoS One; 2021; 16(10):e0258129. PubMed ID: 34618854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The factors associated with negative colonoscopy in screening subjects with positive immunochemical stool occult blood test outcomes.
    Ting PH; Lin XH; Jiang JK; Luo JC; Chen PH; Wang YP; Hsin IF; Perng CL; Hou MC; Lee FY
    J Chin Med Assoc; 2018 Sep; 81(9):759-765. PubMed ID: 29778550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colon capsule endoscopy in colorectal cancer screening: a randomised controlled trial.
    Kaalby L; Deding U; Kobaek-Larsen M; Havshoi AV; Zimmermann-Nielsen E; Thygesen MK; Kroeijer R; Bjørsum-Meyer T; Baatrup G
    BMJ Open Gastroenterol; 2020 Jun; 7(1):. PubMed ID: 32601101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol.
    Wong G; Howard K; Chapman JR; Tong A; Bourke MJ; Hayen A; Macaskill P; Hope RL; Williams N; Kieu A; Allen R; Chadban S; Pollock C; Webster A; Roger SD; Craig JC
    BMC Public Health; 2011 Jun; 11():516. PubMed ID: 21714917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of immunochemical faecal occult blood testing on colorectal cancer incidence.
    Ventura L; Mantellini P; Grazzini G; Castiglione G; Buzzoni C; Rubeca T; Sacchettini C; Paci E; Zappa M
    Dig Liver Dis; 2014 Jan; 46(1):82-6. PubMed ID: 24011791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
    Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
    PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving Participation in Colorectal Cancer Screening: a Randomised Controlled Trial of Sequential Offers of Faecal then Blood Based Non-Invasive Tests.
    Symonds EL; Pedersen S; Cole SR; Massolino J; Byrne D; Guy J; Backhouse P; Fraser RJ; LaPointe L; Young GP
    Asian Pac J Cancer Prev; 2015; 16(18):8455-60. PubMed ID: 26745101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does access to a colorectal cancer screening website and/or a nurse-managed telephone help line provided to patients by their family physician increase fecal occult blood test uptake?: A pragmatic cluster randomized controlled trial study protocol.
    Clouston K; Katz A; Martens PJ; Sisler J; Turner D; Lobchuk M; McClement S;
    BMC Cancer; 2012 May; 12():182. PubMed ID: 22607726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of communication skills training on colorectal cancer screening by GPs: a cluster randomised controlled trial.
    Aubin-Auger I; Laouénan C; Le Bel J; Mercier A; Baruch D; Lebeau JP; Youssefian A; Le Trung T; Peremans L; Van Royen P
    Eur J Cancer Care (Engl); 2016 Jan; 25(1):18-26. PubMed ID: 25851842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of colorectal diseases in immunological fecal occult blood test (I-FOBT) positive patients in a tertiary care hospital in Bangladesh.
    Mollick SH; Roy PK; Bhuiyan MR; Mia AR; Alam MS; Mollick KA; Pervin S; Hassan MQ
    Mymensingh Med J; 2014 Oct; 23(4):764-9. PubMed ID: 25481598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing the effectiveness of a general practice intervention to improve uptake of colorectal cancer screening: a randomised controlled trial.
    Dodd N; Carey M; Mansfield E; Oldmeadow C; Evans TJ
    Aust N Z J Public Health; 2019 Oct; 43(5):464-469. PubMed ID: 31268211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test.
    Koga Y; Yamazaki N; Yamamoto Y; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1844-52. PubMed ID: 23950216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.